Status:
NOT_YET_RECRUITING
Erythropoietin in HIE Neonate
Lead Sponsor:
Assiut University
Conditions:
Neonatal Hypoxic Ischemic Encephalopathy
Eligibility:
All Genders
1-1 years
Phase:
EARLY_PHASE1
Brief Summary
this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal ...
Detailed Description
Hypoxic-ischemic encephalopathy (HIE) remains a major cause of morbidity and mortality. HIE causes 23% of neonatal deaths . Erythropoietin is a 34kDa glycoprotein that was originally identified becaus...
Eligibility Criteria
Inclusion
- \- neonates who less than 1 month suffer from hypoxic ischemic encephalopathy
Exclusion
- neonates who more than 1 month
- neonates who suffer from brain insults other than HIE
Key Trial Info
Start Date :
November 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 24 2029
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT06590155
Start Date
November 24 2024
End Date
February 24 2029
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university children hospital
Asyut, Egypt, 71511